143
Participants
Start Date
December 31, 2015
Primary Completion Date
March 28, 2023
Study Completion Date
March 28, 2023
Monalizumab
Cetuximab
Anti-PD(L)1
Icahn School of Medicine at Mount Sinaï, New York
University of Pennsylvania, Philadelphia
Fox Chase Cancer Center, Philadelphia
University of Chicago, Chicago
Stanford Cancer Center, Stanford
University of California, Moores Cancer Center, La Jolla
University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore
Washington University School of Medicine, St Louis
Vanderbilt University Medical Center, Nashville
Centre Jean Perrin, Clermont-Ferrand
Centre Oscar Lambret, Lille
Centre Leon Berard, Lyon
Hopital La Timone, Marseille
Institut Regional du Cancer de Montpellier, Montpellier
Centre Antoine Lacassagne, Nice
Centre Eugene Marquis, Rennes
ICO Rene Gauducheau, Saint-Herblain
Institut Gustave Roussy, Villejuif
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
Innate Pharma
INDUSTRY